An advisory committee of the Food and Drug Administration has recommended approval for Johnson & Johnson's (JNJ -1.15%) next-generation diabetes treatment canagliflozin, the company announced in a press release. The vote was 10 to 5 in favor of the drug, which, if given final approval, will be sold under the trade name of Invokana.
The medication treats type 2 diabetes in adult patients, and comes in the form of a once-a-day pill. The FDA panel's recommendation comes in spite of concerns about certain cardiovascular risks the drug carries, as well as possible reduced benefits to patients with impaired kidney function.
Canagliflozin was developed by Janssen Research and Development, a unit of Johnson & Johnson.
